MiniMed™ 630G Insulin Pump System Preset levels of background insulin automatically delivered.

With our pump, patients deliver a bolus of insulin with a few button pushes, compared to using an injection.

 

WATCH VIDEO

Overview

INSULIN PUMP THERAPY IS AN EFFECTIVE TREATMENT OPTION FOR MANAGING YOUR PATIENTS WITH TYPE 2 DIABETES.

Some find that using the pump allows them to more discreetly manage their diabetes. Some have also been able to reduce their insulin intake after starting on a Medtronic pump. 1,2

  • More discretion
  • Less insulin required each day
  • Only uses rapid-acting insulin
  • Fewer injections – one injection every 2-3 days vs multiple daily injections

 

“Using a MiniMed™ pump has dramatically changed my life. I no longer have to take multiple daily injections and the preset dosages meet my needs.”
– Doris B. §,||,¶

Doris wearing her MiniMed 630G system.

GUARDIAN™ SENSOR 3

CONTINUOUS GLUCOSE MONITORING (CGM) WITH GUARDIAN™ SENSOR 3 AND GUARDIAN™ LINK 3 TRANSMITTER

With optional CGM, the MiniMed™ 630G pump connects with the Guardian™ Sensor 3 to continuously check glucose levels, detecting highs and lows. It works with SmartGuard™ technology to help patients stay in range.

Guardian Sensor 3 on white background

SMARTGUARD™ TECHNOLOGY

TECHNOLOGY THAT TAKES ACTION TO HELP CONTROL GLUCOSE LEVELS3

SmartGuard™ technology will help your patients spend less time low,*† and more time in range.§ SmartGuard™ technology takes action against lows*3 to help provide advanced protection for your patients:

  • SmartGuard™ technology stops insulin delivery when sensor glucose values reach a preset low limit, and the patient does not respond to alarms.
  • Since its introduction, SmartGuard™ technology has taken action more than 2.1 million times in the U.S. alone — to help patients recover from low glucose events by suspending insulin delivery.
  • 93 percent of people using MiniMed™ systems with SmartGuard™ technology say they feel more secure in treating their diabetes.4
MiniMed 630G system tutorial.

PATIENT-FRIENDLY

EASIER TO USE, SO PATIENTS ARE MORE LIKELY TO SUCCESSFULLY MANAGE THEIR DIABETES

The MiniMed™ 630G system has an intuitive design and several convenient features that can help your patients succeed with their diabetes management. Help your patients make the switch to an insulin pump today.

CONVENIENT FEATURES

  • A color screen with simple menus and auto-brightness
  • Easy-to-navigate screen with simple icons
  • Easy setup instructions and assistance on screen

CUSTOMIZABLE OPTIONS

  • Alerts with customizable volume controls
  • Airplane mode option for travel
Family biking together

Exclusive Linking Meter

The CONTOUR®NEXT LINK 2.4 meter from ASCENSIA Diabetes Care is the only FDA-approved linking meter for use with the MiniMed™ 630G system with SmartGuard™ technology.

Accuracy, CONVENIENCE, AND SIMPLICITY

The high accuracy and precision demonstrated by the CONTOUR®NEXT LINK 2.4 Meter has helped to close the gap between laboratory accuracy and real-word test results.5

Features include:

  • Wireless Connection: Sends highly accurate BG results to the MiniMed™ 630G pump for easy insulin dosing and CGM calibration.
  • USB Connector: Allows for easy downloading to CareLink™ software and battery recharging.
  • Remote Bolusing: Easy-to-use and discreet remote manual and pre-set bolusing feature from the CONTOUR®NEXT LINK 2.4 Meter.
Contour NExt Link 2.4

6-WEEK PUMP EVALUATION PROGRAM

Icon Push Button

Looking for a simple and effective option to recommend for your patients? Your patients can experience insulin pump therapy for 6 weeks. Your local Medtronic Diabetes team can explain the eligibility criteria, which can help you determine which patients would be most appropriate for the 6-week MiniMed™ 630G System Patient Evaluation Program.

GET STARTED

WEBINARS    

On-demand videos offer practical tips from clinical experts for using Medtronic Diabetes therapies to help you support patients.

WATCH NOW

MEDICAL EDUCATION PROGRAMS

Engage with real-world case studies and explore special considerations for therapy management.

LEARN MORE

USER GUIDES AND MANUALS

Browse our library to find reference materials for your Medtronic Diabetes products.

VISIT LIBRARY
*

CGM uses a special sensor to measure sugar levels just below the skin known as interstitial fluid. These sensor glucose (SG) values are different from blood glucose (BG) measurements using a BG meter. Sensor glucose values should not be used to make treatment decisions. Patients should always do a BG fingerstick before they make treatment decisions.

Data from the voluntary Carelink™ Personal Uploads for MiniMed™ 630G and MiniMed™ 530G with Enlite system in US available from Jul 1, 2015 to July 1, 2018 evaluated. Significant difference between SmartGuard™ On vs SmartGuard™ Off.

Assumes 4 injections per day for 30 days and one infusion set change every two to three days.

§

 Individual results may vary.

||

Doris was compensated for spending the day with us and allowing us to photograph her. Thoughts and experiences are her own.

Doris was compensated for spending the day with us and allowing us to photograph her. Thoughts and experiences are her own.

The patient testimonial above relates an account of an individual’s response to treatment. The account is genuine, typical and documented. However, this patient’s response does not provide any indication, guide, warranty or guarantee as to the response other people may have to the treatment. The response other individuals have to the treatment could be different. Responses to the treatment can and do vary. Not every response is the same. Please talk to your doctor about your condition and the risks and benefits of these technologies.

1

Reznik Y, Cohen O, Aronson R, et al. Insulin pump treatment compared with multiple daily injections for the treatment of type 2 diabetes (OpT2mise): a randomized open label controlled trial. Lancet. 2014;384(9950): 1265-1272.

2

Aronson R, Reznik Y, Conget I, et al. Sustained efficacy of insulin pump therapy, compared with multiple daily injections, in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obesity and Meta. 2016; 18:500-507.

3

Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013; 369(3):224–232.

4

User evaluations. Data on file, Medtronic, Northridge, CA.

5

Bailey T, Wallace JF, Greene C, et al. Accuracy and User Performance Evaluation of the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System. Clinica Chimica Acta. 2015;448:139-145.

Important Safety Information: MiniMed™ 630G System with SmartGuard™ technology

Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G or MiniMed™ 530G system are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.

WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.

See www.medtronicdiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

Ascensia Diabetes Care Logo

Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.